UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.
UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.